Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update • ~1.7 million total VOQUEZNA ® prescriptions filled to date • Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 • Q2 operatin
How this was made
The 30-second read
Why it matters
Fresh quarterly performance metrics (revenue growth, expense reductions, cash balance) and updated FY 2026 guidance ranges can drive repricing of revenue trajectory and operating leverage expectations. Pipeline updates (Phase 3 PRN NERD initiation with first enrollment expected Q4 2026; Phase 2 EoE topline expected Q4 2026) add optionality but are not yet definitive outcomes.
Market read
Record Q2 revenue growth, reduced operating expenses, and updated FY 2026 guidance plus near-term clinical catalysts (Q4 2026 enrollment/topline timing) make this a tradable fundamental update for PHAT.
What to watch
The text emphasizes operating profitability excluding stock-based compensation, but GAAP net loss remains; traders may focus on cash burn trajectory and the credibility of gross-to-net assumptions (55-59%) and gross margin (~80%) into 2H.
Background
SEC Form 8-K Item 2.02 reporting Q2 2026 results and a business update for VOQUEZNA, including pipeline progress and updated FY 2026 financial guidance.
Ticker impact
Phathom reported Q2 2026 net revenues of $74.3M (+88% YoY), cut operating expenses, and updated full-year 2026 guidance.
Likely positive bias if investors view the updated guidance as credible and the Phase 3 PRN NERD timeline as de-risking; otherwise could face skepticism on the guidance reset.
This is a primary-source earnings and guidance update with specific figures (revenue, expense reductions, cash balance) and concrete pipeline milestones (Phase 3 enrollment expected Q4 2026, Phase 2 EoE topline expected Q4 2026). The magnitude of the stock reaction depends on how the updated FY ranges compare to Street expectations, which are not provided in the text.
Market effects
Adds incremental datapoints on GI-focused pharma commercialization and the market’s appetite for label-expansion narratives tied to Phase 3 registrational programs.
Primarily US small/mid-cap biotech sentiment via Nasdaq-listed name-specific guidance and clinical timelines.
Limited direct global spillover; could influence broader GI therapeutics sentiment if VOQUEZNA uptake and PRN NERD strategy are viewed as scalable.
Counterpoint
Despite strong Q2 growth, the updated FY 2026 net revenue range is lower than the prior range, which could signal deceleration risk or conservative assumptions for the second half.
Key entities
- issuerPhathom Pharmaceuticals, Inc.
Nasdaq-listed biopharmaceutical company commercializing VOQUEZNA and advancing GI disease pipeline programs.
- productVOQUEZNA
Phathom’s GI therapy whose prescription fill growth and planned label expansion are central to the update.
- indicationNon-Erosive GERD (NERD)
Planned Phase 3 registrational program for as-needed (PRN) VOQUEZNA use, with first subject enrollment expected in Q4 2026.
- indicationEosinophilic Esophagitis (EoE)
Phase 2 pHalcon-EoE-201 trial enrollment completed; topline results expected in Q4 2026.
